Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/9583
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAcheampong, Desmond O.-
dc.contributor.authorAdokoh, Christian K.-
dc.contributor.authorAmpomah, Paulina-
dc.contributor.authorAgyirifo, Daniel S.-
dc.contributor.authorDadzie, Isaac-
dc.contributor.authorAckah, Francis A.-
dc.contributor.authorAsiamah, Ernest A.-
dc.date.accessioned2023-10-17T16:30:06Z-
dc.date.available2023-10-17T16:30:06Z-
dc.date.issued2017-
dc.identifier.urihttp://hdl.handle.net/123456789/9583-
dc.description.abstractAbstract: Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and ra- diotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate per- petual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibod- ies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique char- acteristics. This review discusses up to date therapeutic potentials of BsAbs.en_US
dc.language.isoenen_US
dc.publisherProtein & Peptide Lettersen_US
dc.subjectAntibody,en_US
dc.subjectbispecific antibody (BsAb),en_US
dc.subjectimmunotherapeutic agent,en_US
dc.subjectcancer therapy,en_US
dc.subjectdiabody,en_US
dc.subjectantitumor.en_US
dc.titleBispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapyen_US
dc.typeArticleen_US
Appears in Collections:School of Allied Health Sciences

Files in This Item:
File Description SizeFormat 
Bispecific Antibodies (bsAbs) Promising Immunotherapeutic Agents for.pdfMain article747.5 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.